|
07th November 2009
|
During his 4-day high-profile visit to Egypt, president of Rwanda Paul Kagame and a political delegation payed an attendance to Minapharm pharmaceuticals and Rhein-Minapharm Biogenetics (currently MiGenTra Egypt), Africa’s first and only gene-to-market biopharmaceutical company manufacturing end-to-end self-developed biosimilar products.
|
Bardissi & Kagame at Africa’s only gene-to-market biopharmaceutical company (MiGentra)
|
|
The visit included an introductory presentation through Dr. Wafik Bardissi, Minapharm Chairperson and CEO, presenting Minapharm pharmaceuticals leadership in establishing the first process R&D and bio-manufacturing facility in African region to develop, manufacture, and commercialize advanced therapeutic recombinant proteins in the fields of hepatitis C, thrombosis, haemostasis and infertility.
|
|
|
|
|
The president of Rwanda at Minapharm biotechnology factory guided by Dr. Wafik Bardissi
|
|
|
|
Dr. Wafik Bardissi accompanied the president Mr. Paul Kagame on a guided tour through Rhein-Minapharm’s unique process R&D labs, and biotechnology production facility as well as a route through Minapharm pharmaceuticals prime facility.
|
|